Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Oct 06, 2022 12:40pm
211 Views
Post# 35009770

Herpes is the cause

Herpes is the causeWasnt  Rudi Tanzi speculating that herpes had some connection to AD ... 

In a new therapy alternative, using a virus to kill the cancer cells is showing good promise in early human trials as per UK scientists. A patient from London has claimed that a similar treatment cured him of the disease. While the drug cured a man completely, others had their tumours got shrink following the intake. As per reports, the drug is a weakened form of the cold sore virus (herpes virus) that has been modified to attack cancer cells.

As per reports, a London man, diagnosed with cancer of the salivary gland was one of the patients who took the new alternative viral therapy initiated by the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust of the UK. The man took many surgeries and treatments that remained ineffective for his condition. In a desperate search for hope, he had agreed to be a part of the first clinical trial. Little did he knew that the treatment would cure him of his terminating sickness. The man is reportedly cancer-free for two years now. 
<< Previous
Bullboard Posts
Next >>